NonprofitsTranslational Genomics Research Institute Foundation

Medical Research

Translational Genomics Research Institute Foundation

PHOENIX, AZ

Total revenue

$11.0M

Total expenses

$11.6M

Net assets

$12.1M

Grants received

$26.1M

95 grants

EIN

331092191

Tax year

2023

Mission

Fundraising and development functions for The Translational Genomics Research Institute ("TGen"), Western Regional Medical Center, Inc. ("COH Phoenix") and their respective affiliates, which are 501(c)(3) tax-exempt organizations.

Financials

FY 2023

Revenue

Contributions & grants$10.5M
Program service revenue
Investment income$592K
Other revenue
Total revenue$11.0M

Expenses

Grants paid$9.7M
Salaries & benefits$1.5M
Fundraising$1.7M
Other expenses$459K
Total expenses$11.6M
Total assets$22.8M
Net assets$12.1M

People

24 listed

NameRoleCompensation

BENNETT DORRANCE

BOARD MEMBER/CHAIRMAN

Board

1 hrs/wk

ERIN MASSEY

CHIEF DEVELOPMENT OFFICER

Board

40 hrs/wk

KEN KENDRICK

BOARD MEMBER/SECRETARY

Board

1 hrs/wk

RICHARD J LEHMANN

BOARD MEMBER/TREASURER

Board

1 hrs/wk

ALAN POWELL

BOARD MEMBER

Board

1 hrs/wk

BILL POPE

BOARD MEMBER

Board

1 hrs/wk

CATHERINE IVY

BOARD MEMBER

Board

1 hrs/wk

DAVID LANE

BOARD MEMBER

Board

1 hrs/wk

FRED SHAULIS

BOARD MEMBER

Board

1 hrs/wk

GLENN D STEELE MD PHD

BOARD MEMBER

Board

1 hrs/wk

HOWARD YOUNG

BOARD MEMBER

Board

1 hrs/wk

J DANFORTH QUAYLE

BOARD MEMBER

Board

1 hrs/wk

JEFFREY M TRENT PHD

BOARD MEMBER

Board

1 hrs/wk

KEVIN TULIPANA DO MS

BOARD MEMBER

Board

1 hrs/wk

LYNDA CARTER ALTMAN

BOARD MEMBER

Board

1 hrs/wk

MICHEAL KAPLAN

BOARD MEMBER

Board

1 hrs/wk

MIKE INGRAM

BOARD MEMBER

Board

1 hrs/wk

PHIL FRANCIS

BOARD MEMBER

Board

1 hrs/wk

STEVE HILTON

BOARD MEMBER

Board

1 hrs/wk

STEVE STAGNER

BOARD MEMBER

Board

1 hrs/wk

TERESA BURLESON

BOARD MEMBER/TGEN COO

Board

1 hrs/wk

TROY RICHARDS

BOARD MEMBER

Board

1 hrs/wk

WILLIAM J POST

BOARD MEMBER

Board

1 hrs/wk

MANUEL ESTRADA

CFO/ASSISTANT TREASURER

Board

0

Grants received

Showing 95 of 95

FromAmountPurposeYear
$950K
Research
2024
$250K
To support pancreatic cancer research program
2024
$50K
OPERATIONAL SUPPORT
2024
$25K
PROGRAM SUPPORT
2024
$5K
UNRESTRICTED GENERAL SUPPORT
2024
$150
GENERAL EXEMPT PURPOSE
2024
$24
GENERAL SUPPORT
2024
$3.0M
ESTABLISHMENT OF THE ROBERT & LYNDA CARTER ALTMAN FAMILY RESEARCH FUND WITH TGEN AND ITS AFFILIATE, CITY OF HOPE, TO FACILITATE RESEARCH EFFORTS IN TWO COMPLEMENTARY AREAS SPECIFICALLY DESIGNED FOR RAPID IMPROVEMENT OF PATIENT OUTCOMES WHO SUFFER FROM MPN/SAML. ONE RESEARCH PROJECT, THE THERAPEUTIC RESEARCH PROJECT, TO BE CONDUCTED BY THE CITY OF HOPE WILL COMPREHENSIVELY TEST AND SCALE UP THE MANUFACTURE OF THE DRUG DENOMINATED AS MIR-142. THIS "MIMETIC" DRUG SIMULATES (REPLACES) THE ACTION OF A NORMAL SIGNAL THAT IS MISSING IN MPN/SAML PATIENTS.
2023
$2.7M
ESTABLISHMENT OF THE ROBERT & LYNDA CARTER ALTMAN FAMILY RESEARCH FUND WITH TGEN AND ITS AFFILIATE, CITY OF HOPE, TO FACILITATE RESEARCH EFFORTS IN TWO COMPLEMENTARY AREAS SPECIFICALLY DESIGNED FOR RAPID IMPROVEMENT OF PATIENT OUTCOMES WHO SUFFER FROM MPN/SAML. ONE RESEARCH PROJECT, THE DIAGNOSTIC RESEARCH PROJECT, IS TO BE CONDUCTED BY TGEN TO DEVELOP TWO DIAGNOSTIC TESTS. THE FIRST DIAGNOSTIC RESEARCH PROJECT IS TO IDENTIFY THE MOST SENSITIVE TEST FOR THE TRANSITION FROM MPN TO SAML. THE SECOND DIAGNOSTIC RESEARCH PROJECT IS TO DEVELOP AND DEPLOY AN ULTRA-RAPID WHOLE GENOMIC SEQUENCING TEST TO IDENTIFY DRUG TREATMENT OPTIONS FOR PATIENTS WHO HAVE TRANSITIONED FROM MPN TO SAML.
2023
$650K
Research
2023
$508K
SEE PART IV
2023
$171K
GENERAL SUPPORT
2023
$85K
KIDNEY DISEASE TREATMENT AND RESEARCH
2023
$44K
GRANT AWARD-MIND/CROWD PROJECT
2023
$25K
PROGRAM SUPPORT
2023
$15K
For grant recipient's exempt purposes
2023
$10K
GENERAL PROGRAM ASSI
2023
$7K
HUMAN SERVICES
2023
$5K
UNRESTRICTED GENERAL SUPPORT
2023
$72
GENERAL SUPPORT
2023
$72
GENERAL SUPPORT
2023
$72
GENERAL SUPPORT
2023
$48
GENERAL SUPPORT
2023
$32
GENERAL SUPPORT
2023
$4.3M
GENERAL PURPOSE
2022
$3.1M
ESTABLISHMENT OF THE ROBERT & LYNDA CARTER ALTMAN FAMILY RESEARCH FUND WITH TGEN AND ITS AFFILIATE, CITY OF HOPE, TO FACILITATE RESEARCH EFFORTS IN TWO COMPLEMENTARY AREAS SPECIFICALLY DESIGNED FOR RAPID IMPROVEMENT OF PATIENT OUTCOMES WHO SUFFER FROM MPN/SAML. ONE RESEARCH PROJECT, THE DIAGNOSTIC RESEARCH PROJECT, IS TO BE CONDUCTED BY TGEN TO DEVELOP TWO DIAGNOSTIC TESTS. THE FIRST DIAGNOSTIC RESEARCH PROJECT IS TO IDENTIFY THE MOST SENSITIVE TEST FOR THE TRANSITION FROM MPN TO SAML. THE SECOND DIAGNOSTIC RESEARCH PROJECT IS TO DEVELOP AND DEPLOY AN ULTRA-RAPID WHOLE GENOMIC SEQUENCING TEST TO IDENTIFY DRUG TREATMENT OPTIONS FOR PATIENTS WHO HAVE TRANSITIONED FROM MPN TO SAML.
2022
$1.3M
ESTABLISHMENT OF THE ROBERT & LYNDA CARTER ALTMAN FAMILY RESEARCH FUND WITH TGEN AND ITS AFFILIATE, CITY OF HOPE, TO FACILITATE RESEARCH EFFORTS IN TWO COMPLEMENTARY AREAS SPECIFICALLY DESIGNED FOR RAPID IMPROVEMENT OF PATIENT OUTCOMES WHO SUFFER FROM MPN/SAML. ONE RESEARCH PROJECT, THE THERAPEUTIC RESEARCH PROJECT, TO BE CONDUCTED BY THE CITY OF HOPE WILL COMPREHENSIVELY TEST AND SCALE UP THE MANUFACTURE OF THE DRUG DENOMINATED AS MIR-142. THIS "MIMETIC" DRUG SIMULATES (REPLACES) THE ACTION OF A NORMAL SIGNAL THAT IS MISSING IN MPN/SAML PATIENTS.
2022
$300K
CANCER RESEARCH
2022
$262K
GENERAL SUPPORT
2022
$120K
KIDNEY DISEASE TREATMENT AND RESEARCH
2022
$50K
OPERATIONAL SUPPORT
2022
$40K
For grant recipient's exempt purposes
2022
$9K
DONATIONS MADE TO TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION
2022
$9K
SEE PART IV
2022
$256
GENERAL SUPPORT
2022
$100
CHARITABLE
2022
$96
GENERAL SUPPORT
2022
$547K
PARKINSON'S RESEARCH
2021
$200K
CANCER RESEARCH
2021
$137K
PROGRAM SUPPORT
2021
$60K
KIDNEY DISEASE TREATMENT AND RESEARCH
2021
$50K
OPERATIONAL SUPPORT
2021
$13K
For grant recipient's exempt purposes
2021
$13K
For grant recipient's exempt purposes
2021
$8K
See Part IV
2021
$1.2M
Research
2020
$1M
CANCER RESEARCH
2020
$490K
CANCER RESEARCH
2020
$146K
PROGRAM SUPPORT
2020
$78K
TO ESTABLISH THE OCNDS RESEARCH PROGRAM
2020
$50K
DESIGNATED SUPPORT FOR COVID-19 TESTING
2020
$50K
SUPPORT CHARITY ORG
2020
$33K
FOR RECIPIENT'S EXEMPT PURPOSE
2020
$25K
KIDNEY DISEASE TREATMENT AND RESEARCH
2020
$25K
OPERATIONAL SUPPORT
2020
$15K
For grant recipient's exempt purposes
2020
$500K
Research
2019
$306K
PROGRAM SUPPORT
2019
$150K
GENERAL SUPPORT
2019
$60K
KIDNEY DISEASE TREATMENT AND RESEARCH
2019
$21K
SEE PART IV
2019
$19K
For grant recipient's exempt purposes
2019
$1.0M
CANCER RESEARCH
2018
$276K
Program Support
2018
$275K
Cancer Research
2018
$173K
PROGRAM SUPPORT
2018
$120K
Research
2018
$50K
OPERATIONAL SUPPORT
2018
$15K
See Part IV
2018
$3K
Gainey Village Hike
2018
$2K
Fitness for the Cure (formerly known as Cycle for the Cure)
2018
$245K
PROGRAM SUPPORT
2017
$10K
See Part IV
2017
$6K
HEALTH & HUMAN SERVICES
2017
$5K
GENERAL OPERATING EXPENDITURES
2017

Funded by

$26.1M from 35 funders · 95 grants · 2017–2024

The Robert & Lynda Altman Family

$14.3M · 5 grants · 2022–2023

Purple Pansies Inc

$3.4M · 5 grants · 2018–2024

The Seena Magowitz Foundation Inc

$2.5M · 4 grants · 2018–2022

Arizona Community Foundation

$1.4M · 7 grants · 2017–2023

Helios Education Foundation

$949K · 7 grants · 2017–2023

The Michael J Fox Foundation

$547K · 1 grant · 2021

Animal Cancer Foundation

$490K · 1 grant · 2020

Arizona Women's Board

$350K · 5 grants · 2019–2023

Details

EIN331092191
NTEE codeH112
Subsection03
Ruling date2004-09
Formed2004
Employees0
Volunteers100
TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION — Mission, Financials & Grants Received | Grantivo